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SUMMARY: 
Maxillofacial surgery can be used to help appearance and restore function.  Often there is 
a need to provide additional volume with soft tissue properties. This works explores the 
use of a new biomaterial invented at GT with soft tissue properties as possible 
maxillofacial implants to provide volume.  The implants are for restoring speech function 
in cleft palate patients presenting velopharyngeal insufficiency and providing volume to 
reduce the nasolabial folds in order to create a more youthful appearance. 
We have developed facial implants for the nasolabial fold and lip plumping to address 
low efficiency of the current methods employed for dermal fillers by providing both 
long-term usage as well as removability. Furthermore, an insertion method and insertion 
tools were developed to facilitate the implantation for the surgeons. 
Regarding the reconstructive aspects of the maxillofacial implants, we have developed a 
pharyngeal implant aiming to reduce the gap between the pharyngeal implant and the 
velum (soft palate) of 20% of patients presenting a cleft palate. This implant will allow 
the care team to delay the palatoplasty in order to not hinder palatal growth in patients. 
The material used for the implants can also be used to better the current obturators by 
replacing the acrylic, posterior portion. The main current obturators are the nance 
obturator and custom acrylic obturators, deemed uncomfortable for the patients due to the 
hardness of the material. The design process for the implants and the novel obturator 
involved the optimization of material and shape, taking into consideration mechanical 
properties of the implants’ surrounding tissues, the anatomy of each feature being 
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Part 1: Cleft palate 
 
Chapter 1: Background 
 
1.1 Description of the condition 
 A cleft palate is an oral birth defect that happens during the early stages of a fetus’ 
development, affecting the roof of the patient’s mouth. The cause is currently unknown, 
but scientists believe it is a combination of genetic and environmental factors. Each year, 
approximately 2650 children are born in the US with a cleft palate. The cleft could be 
unilateral or bilateral, and it could affect the soft palate, the hard palate or both, 
depending on the severity. [1, 2] 
 
Figure 1: normal palate vs partial cleft palate and complete, unilateral cleft palate  
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Figure 2: Representation of the most common types of cleft affecting the palate. (a) 
Unilateral cleft lip with alveolar involvement; (b) bilateral cleft lip with alveolar 
involvement; (c) unilateral cleft lip associated with cleft palate; (d) bilateral cleft lip and 
palate; (e) cleft palate only.[3] 
 
1.2 Problems caused by the condition:  
 In a pediatric patient presenting with a cleft palate, speech production, dentition, 
feeding and maxillofacial growth are affected. Feeding is the most critical challenge 
faced by parents of babies born with cleft lip/palate. [4, 5] Not only appropriate feeding is 
important for the infants’ adequate development, but also the volume of milk intake must 
be sufficient for adequate weight gain prior to surgical repair of the cleft lip and or palate. 
[4-6] 
 Studies have shown a significant difference in weight between babies with cleft 
palates and babies without, as well as levels of weight discrepancies depending on the 
type and extensity of cleft[7]. Babies with more extensive complete clefts suffer of poorer 
oral intake thus tend to weigh less than babies with smaller complete clefts, while babies 
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with incomplete clefts generally weigh less than babies with complete clefts. The reason 
behind the latter is that incomplete clefts are less often detected as early as complete 
clefts.[8] Parental and infantile frustration during the feeding process can also affect the 
parent-child bonding process.  
 Different feeding strategies have been developed to address this problem, 
depending on the type of cleft the baby is presenting. The ability to produce both positive 
and negative pressure for suction and release of the nipple during the feeding process is 
the most important criteria for infant feeding.  
Cleft Palate only case:  
 In the case of a narrow cleft affecting only the soft palate, the baby is able to 
adjust and eventually develop sufficient suction for breastfeeding. When the hard palate 
is affected however, the patient is more likely to have long-term difficulty producing 
adequate suction because of a smaller palatal surface available for the tongue to apply 
pressure.[5] In this case, bottle-feeding is a better feeding option compared to 
breastfeeding. Table 1 describes the types of commercially available bottles for cleft 
palate patients. 
Table 1: Types of nipples available for cleft palate feeding bottles [5] 
Nipple Type  Pliability  Flow Rate  Shape  Hole Type  
Preemie Soft  Fast  Traditional  Hole and cross-cut  
NUK-style  Soft  Fast  Broad, Flat  Hole on top surface of tip 
Ross Cleft  Soft  Fast  Long, Thin Large hole  
Standard  Medium  Low  Traditional  
Hole and cross-cut, several 
holes  
Mead Johnson Soft 
Feeder 
regulated  Customized  Cross-cut  
Haberman 
System Soft  
Feeder 
regulated  Customized  Slit  
	  























Figure 4: Details of a Haberman Feeder [6] 
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Cleft lip and palate case:  
The cleft lip hinders infants from properly creating a seal around the nipple of the breast 
or the feeding bottle, which directly affects their ability to produce adequate pressure for 
suction or releasing of the nipple. Additionally, the patients with cleft lip and palate 
present larger palatal clefts, contributing to the intraoral pressure insufficiency.  
Breastfeeding is therefore of very little likelihood in patients presenting both cleft lip and 
palate. [5] Although there still is some difficulty present with the usage of feeding bottles, 
they are significantly better alternative for these patients.  
In addition to feeding bottles, palatal obturators are used to create provide more area on 
the roof of the mouth to allow the tongue to produce more pressure during feeding.[9] 
Obturators are prosthetic devices made to fit in the roof of the mouth and cover the gap.  
Palatal obturators are typically made out of acrylic on a per patient basis, depending on 
each patient’s anatomy. As the patients grow, the type of obturator changes from a full 
palatal obturator covering the entire palate to a partial palatal obturator, anchored at the 
molars and covering mainly the cleft. [5] These palatal obturators are risky for the 
patients because of the material qualities of acrylic: because of its hardness, it can cut the 
patient’s tongue or create ulcerations on the patient’s palate. There is therefore a need in 
the field for obturators to be made out of a softer material.  
The second most critical concern for parents of infants presenting a cleft palate is the 
predisposition for a speech impediment as they grow.  [10, 11]The speech production 
problem faced by many cleft palate patients is due to velopharyngeal insufficiency (VPI). 
The velopharyngeal valve plays an important role during speech production, primarily 
directing airflow and sound energy into the oral and nasal cavities. VPI is defined as an 
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inadequate physiological barrier between the naso-pharynx and oropharynx during 
speech, due to the dysfunction of the coordinated movements of the velum (soft palate) 
and a wider than usual posterior gap between the soft palate and the posterior pharyngeal 
gap [4, 5, 12]. In approximately 20% of cleft palate patients, the velum is unable to reach 
the pharyngeal wall for the proper production of sounds. [5]Unfortunately, in some cases 
VPI persists in patients even after palatoplasty (palatal closure). Studies have determined 
the factors that influence persistent VPI post-palatoplasty in order to predict the 
occurrence. The posterior gap between the velum and the pharyngeal wall and the width 
of the cleft at the hard palate level are the main criteria used for VPI prediction [13]. 
Platelet rich plasma and autologous fat injection on the pharyngeal wall is done in order 
to boost the wall’s thickness and reduce the posterior gap between the velum and the 
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1.3 Surgical Treatment:  
A palatoplasty, consisting of the repositioning of tissues and muscles in order to close the 
cleft and rebuild the roof of the mouth, is performed when the patient is deemed ready by 
the surgeon. This surgical treatment may occur in one or two steps, depending on the size 
of the cleft [15, 16]. Clefts deemed as particularly large are treated in a two-step manner, 
where the first surgery, the soft palate closure may occur as early as 3-4 months, followed 
by a hard palate closure, usually when the patient is 18 months old[15].  In cases where 
the physician considers the cleft small, the palatoplasty is usually accomplished at age 11 
months. The timelines for surgical planning vary per patients, depending on whether they 
meet certain preoperational criteria such as hemoglobin levels of at least 10 g/dL, weight 
gain, and lack of infection.[11, 16] Palatoplasties occurring at a later stage are usually 
accompanied with a pharyngeal flap to better the speech production phase of the child’s 
growth [17, 18]. 
The purpose of the palatoplasty is to create separation between the oral and nasal to 
facilitate both feeding and speech production post surgery. The benefits from this 
treatment are evidently significant, however, studies have shown that early palatal closure 
negatively affects longitudinal palatal growth[18, 19].  Additionally, the risk for 
maxillofacial growth abnormalities is increased. The palate usually reaches its optimal 
size at age 5, but waiting this long before performing the palatoplasty at this stage of the 
child’s development has a significantly negative effect on the child’s speech 
development, and potentially have some effects on the child’s social and emotional 
development.  
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Figure 6: description of pharyngeal flap insertion in patients suffering of velopharyngeal 
insufficiency[14] 
 
1.4 Deficiencies that need to be addressed: 
Early palatoplasties affect the maxillary arch growth and can potentially lead to some 
maxillary development abnormalities, while delaying the procedure too far can 
tremendously affect the patients’ speech and socio-emotional development[17, 20, 21]. 
There is thus a need for a form of treatment that would allow sufficient palatal growth, 
while still assisting the speech production at an early stage. Additionally, it is important 
to look at ways to reduce the risks associated with the obturators due to acrylic’s 
hardness. 
1.5 Proposed Solution 
In order to address the deficiencies related to the timelines of surgical procedures and 
medical treatments of the cleft palate, this research came up with two separate devices: an 
implant that would be inserted into the pharyngeal wall, underneath the skin in order to 
shorten the velopharyngeal gap and a softer obturator to cover the palatal cleft.   
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Chapter 2: Market Analysis 
2.1 Market overview 
Every year in the United States, approximately 2500 children are born with a cleft palate 
or cleft lip and palate. The average cost involved in the treatment and accommodations of 
a patient with a cleft palate from birth to adulthood is $100,000. This device may reduce 
the cost of the cleft palate surgical treatment by one half, from potentially $20,000 to 
$10,000 [22]. This cost reduction could come from delaying and reducing of the number 
of surgical procedures performed during the typical treatment timeline.  Additionally, 
because the implant will be ideally placed before the patient’s speech pattern begins to 
develop, the cost of speech therapy may be significantly reduced. Speech therapy is 
estimated at $100/hour, and the number of hours needed strictly depend on the patient 
and the severity of the speech impediment.  
1.2 Patient Profile 
The patients that would be considered for the pharyngeal implant are the 20% of cleft 
palate patients suffering of velopharyngeal insufficiency, ranging from age 0 to 5 years.  
The majority of cleft palate patients wear palatal obturator during the course of their 
treatment; therefore the palatal obturator’s design is applicable to a wide range of cleft 









Chapter 3: Design considerations 
                     
3.1 Design controls overview 
Design controls specify the formal methodology followed during the product 
development process. Several regulatory agencies such as the Food and Drug Authority 
(FDA) and the Environmental Protection Agency (EPA) make the implementation of this 
process mandatory for designers and manufacturers of new products. The FDA offers 
specific guidance for design controls of medical devices. This process entails the 
definition of design input, obtaining design outputs, reviewing the design, verifying the 
design and validating the design and documenting all phases of the process with design 
history file [23]. 
  




Design inputs are the starting line of the design of a product: during this part, the designer 
takes into consideration the end users’ needs  (patient and healthcare practitioner) and 
translates these needs into design criteria for the device for the device’s functionality.  
Once the design inputs have been established, the designer comes up with product 
concepts that may be altered depending on the changes made to the design input of the 
device. The verification phase involves the different tests that need to be effectuated to 
verify that the device design meets the predefined criteria in the design input section. 
Lastly, the device validation phase involves making sure that the device will conform to 
user needs without having unwarranted adverse effects. This phase involves effectuating 
a device risk analysis, risk mitigation and potentially clinical trials, depending on the type 
of device. In the case of this research, the risk analysis and risk mitigation were the steps 
taken for the device validation. [25] 
Design Input 
 
In order to determine the design input for a device, the main customers’ requirements are 
determined. Customers are defined as the end users of the devices being designed. It is 
important to note that for this research, two devices are being developed to assist with 
cleft palate problems: One implant to help with speech production, and a de novo palatal 
obturator.  
Customer identification:  
 
The primary costumers for the pharyngeal implant and de novo palatal obturator are the 





3.2 Customer needs:  
The following tables describe each consumer’s needs per device. Because certain needs 
may counteract with others, a Design Control process is used to minimize the risks for the 
devices and preserve the effectiveness.  
 
Table 2: Customer needs for the pharyngeal implant 
 
Patient Needs  
1 Pharyngo-palatal gap reduced, leading to better speech production 
2 Safe device 
3 Long life of device 
4 Reduce cost of long term care 
5 Minimized need of additional surgeries 
6 No discomfort from implanted device 
  
 
Surgeon Need  
1 Reduce frequency of treatment using device compared to current treatment 
2 Wide range of device size to select from 
3 Standardized method for selection of size 
6 Device that is tactile 











Table 3: Customer needs for the palatal obturator 
 
Patient Needs  
1 Oro-nasal fistula covered/filled while giving a more comfortable feel 
2 Safe device 
3 Removable device  
4 Long life of device  
5 Reduce cost of long term care  
6 Minimized need of additional surgeries  
7 No discomfort from implanted device  
  
 
Physician Need  
1 Reduce frequency of treatment using device compared to current treatment  
2 Wide range of device size to select from 
3 Standardized method for selection of size  
4 Device that is tactile  
5 Diagram and procedures for best practices of positioning and delivering 
 
The customers’ needs were determined by surveying physicians as well as finding current 
problems in the field from published case studies. These customer needs are then 
translated into quantifiable and measurable engineering parameters using a quality 
functional deployment (QFD) chart. A QFD is defined as a structured approach used to 
defining customer needs and succinctly translating said needs into specific plans to 
produce the product to meet those needs [26] 
The primary needs of the customers were evaluated and described in two main 
categories: ease of implantation and functionality after implantation.  
 
The ease of implantation category covers the requirements related to the surgeons’ needs. 
One of the main clinician goals is to increase the patient throughput without jeopardizing 
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necessary time in the hospital, therefore minimizing the time of the procedure by making 
the device easily implantable and making the insertion the least complex possible will 
help accomplishing this goal. Additionally, a set method for implant size selection should 
be implemented in order to minimize potential complications and improve patient 
satisfaction.  
Functionality after implantation as a category encompasses the physical role the implant 
is meant to play. This therefore addresses needs of the patients, the surgeons, insurance 
companies and hospitals. For example, for a patient receiving a pharyngeal wall implant, 
the velopharyngeal gap must be shortened well enough in order to enhance speech 
production.  In the same breath, such implants must not cause immune reactions, 
infections, or migrate from their site of insertion.   
3.3 Linking Requirements to parameters 
Once the engineering parameters were identified and consumer requirements specified, 
each parameter was evaluated to determine which consumer requirement it addresses in 
the respective QFDs. This work tested for those parameters, evaluating the functionality 
of each device. Elements such as the shape, size and softness (elasticity) of the 
pharyngeal implant and posterior portion of the palatal obturator, and how close the 
material could be to human adipose/muscle tissue in terms of mechanical properties were 
critical for the creation of each device. These criteria drove the evaluation of the devices 






Table 4: QFD translating customer needs to design inputs for the pharyngeal implant 
 
Design Inputs 


































































Ease of Implantation  
           Wide range of device size to select from 
  
* * * 
      Standardized method for selection of size 
 
* * * * 
      Functionality after Implantation  
           Minimized need for additional surgeries * 
     
* 
    Improved speech production due to reduced 
Velopharyngeal gap 
  
* * * 
      Long life of device * 
     
* * * 
 
* 
Critical Functionality tests  1 - - - - - - 2 3 4 - 
 
 
Table 5: tests performed to verify properties of the pharyngeal implant 
Test Type 
1 Compression Test 
2 Tensile Strength Test  
3 Tear Strength Test 










Table 6: QFD translating customer needs to design inputs for the palatal obturator 
 Design Inputs 



































































           Insertion causes minimal local trauma 
 
* * * 
       Safe device 
     
* * * * 
 
* 
Wide range of device size to select 
from 
  
* * * 
      Standardized method for selection of 
size 
 
* * * * 
      Functionality after Implantation  
           Improved speech production due to 
reduced oro-nasal communication 
 
* * * * 
      Reduce risk of treatment using device 
compared to current treatment * 
     
* * * * 
 Long life of device *      * * *   












3.4 Design Inputs  
The most critical design specifications for these devices are encompassed by the 
geometric characteristics, the mechanical property, and sterility.  The tables below break 
every design characteristic into specific items and outlines to boundary for each.  
Table 7: Design Inputs for the pharyngeal implant 
Item  Design Parameter  Design Specification  
A Elasticity 
The material used for the pharyngeal implant must have a 
modulus of elasticity less than 200 kPa and greater than 50 
kPa 
B Shape 
The pharyngeal wall implant must be a cube/block of the 
polymer that can be carved by the surgeon  
C Length  The length could range from 10 to 20 mm  
D Height  The height will be 5 mm 
E Depth  The depth will be 5 mm  
F Biocompatibility The implant meets ISO 10993 requirements for implants  
G Removability Remains intact and solid, does not dissolve in the body 
H Tensile Strength The material used has a tensile strength of at least 25 kPa 
I Tear Strength The material used has a tear strength of at least 30 mN/mm 
J Swellability  
The material selected must neither swell by more than 10% 
in physiological conditions nor must it shrink 
K Asepticity/sterility Implant meets tripartite sterility test requirements  
L Low fibrosis 
The implant must not adhere or react to the surrounding 











Table 8: Design Inputs for the palatal obturator 
Item  Design Parameter  Design Specification  
A Elasticity 
The material used for the posterior portion of the obturator 
must have a modulus of elasticity less than 1 MPa and 
greater than 200 kPa 
B Shape 
The pharyngeal wall implant must be a cube/block of the 
polymer that can be carved by the surgeon  
C Width 3-6 cm (patient specific) 
D Height  5-10 mm (patient specific) 
E Length  3-6 cm (patient specific) 
F Biocompatibility The implant meets ISO 10993 requirements for implants  
G Removability Remains intact and solid, does not dissolve in the body 
H Tensile Strength The material used has a tensile strength of at least 25 kPa  
I Tear Strength The material used has a tear strength of at least 30 mN/mm 
J Swellability 
The material selected must neither swell by more than 15% 
in physiological conditions, nor must it shrink 
K asepticity/sterility Implant meets tripartite sterility test requirements  
 
 
3.5 Justification of design specifications 
Pharyngeal Implant  
• Shape, Length, Height and Depth – the pharyngeal wall implant is designed to 
be a block of polymer than can be carved and shaped by the surgeon based on the 
anatomy of the patient being treated. The dimensions of the block are to be as 
recommended from surgeons, and recorded dimensions of velopharyngeal gap in 
CP patients.  
• Asepticity/Sterility – the implants must be sterile when inserted into the patient, 
and not lead to any infection 
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• Biocompatibility – The implant must be completely compatible with the human 
body in order to avoid any form of immune reaction or lead to dangerous 
consequences such as development of cancerous cells  
• Tensile and Tear Strength – both were determined experimentally by pulling a 
sample implant from an extensometer using surgical forceps and recording the 
load. This was necessary because it is part of the criteria covered by the 
removability of the implant.  
• Swelling – The swelling ratio of the implants is determined by inserting 
blocks of the material used into saline baths, and measuring the samples’ 
weight until a plateau is reached, in the order of days.  The implant pharyngeal 
wall implant should not show a swelling ratio of more than 10% because a 
significant increase in volume could lead to the tear of stitches during the early 
stages, and potential implant migration and partial airway obstruction 
• Compressive modulus of elasticity: the implant must be firm and provide a base 
that is not too hard. Additionally, the pharyngeal wall is mostly composed of 
muscle and connective tissue; therefore it is best to use a material of elasticity 
similar to that of skeletal muscle tissue.  
• Low fibrosis: The material selected for the implant must not adhere to the 
local/surrounding tissue in case of long-term complication. It is important that the 
implant has not adhered to the surrounding tissue if the need to remove it present 
itself, for example in the event of a potential local infection.  
De Novo Palatal Obturator 
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• Dimensions & shape This obturator is patient specific, and the posterior part is 
what we are focusing on as part of this work. It is meant to be a block of polymer 
attached to a rigid acrylic frontal part by a metallic hook. The block of polymer is 
meant to be carved by the surgeon based on the dimensions and type of the cleft 
affecting the palate.  
• Asepticity/Sterility – the implants must be sterile when inserted into the patient, 
and not lead to any infection 
• Tensile and Tear Strength: The material used for the posterior part of the 
obturator must resist tear and tension from potentially repeated removal and 
patient-device interaction: material tensile strength greater than 25kPa, and tear 
strength greater than 30 mN/mm. 
• Compressive Modulus of elasticity: The posterior part of the palatal obturator 
should be firm enough to resist recurrent placement and removal, but still be 
softer in compression than the current acrylic obturators. Additionally, the palate 
being mainly composed of cartilage, it is important that the elasticity range 
selected for the obturator is of the same order as that of cartilage (0.5-0.9 MPa) 
[27] 
• Dimensional Stability: A significant change in the posterior part of the obturator 
will affect how it fits into the patient’s cleft and may have consequences on the 
intraoral pressure necessary for speech production as well as swallowing, and may 
lead to ulcerations on the patient’s palate.   
 
Prior to deciding on designing two separate devices (pharyngeal wall implant and de 
novo palatal obturator), several concepts of a device that would work as a valve 
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separating the oral and nasal cavities, facilitating speech production as well as proper 
feeding for the patients.  
 
Chapter 4: Concept Development 
4.1 Materials Selection 
 
Various biomaterials are researched and used in patient care. Because the FDA clears 
devices and not materials, it is simpler to choose a material used in previously approved 
devices. The main goal of this research was to design functional, solid and removable 
maxillofacial implants for eventual clinical use in the cosmetic and reconstructive fields 
of plastic surgery. Silicone, PMMA, Hard Tissue Replacement polymer, polyesters, 
biodegradable polyesters  (Poly-L-Lactic Acid, Polyglycolic acid) Polyethylene, and 
polypropylene are some materials used in maxillofacial implants [28, 29]. 
The characteristics of the material to be used were determined by observing those of the 
surrounding tissues, as well as each type of implant’s design constraints. Because this 
research aimed at coming up with removable long term implants, it was deemed 
important to select a non-biodegradable material. The table below compares and contrasts 
different materials currently used in maxillofacial implants. Based on each material’s 
characteristics. The leading criteria that lead to selecting PVA as the material for the 
implant is its inertia/non-adhesion to human tissue. A solid implant is removable in case 
of potential long-term complications. For the obturator, it was the new design objective 
that implant be more elastic, since the main issue with acrylic obturators is hardness, 




Table 9: List of materials used for maxillofacial implants and prosthesis and their 
characteristics  
Material  FDA Approved Toxic Microspheres Solid  Tissue Adhesion Soft Tissue-like elasticity 
PVA  Yes No No Yes No Yes 
PMMA  Yes  Yes Yes  Yes No No 
ePTFE Yes  No No Yes No No 
PET  Yes No No Yes Yes No 
Acrylic Yes No No Yes No No 
 
Poly (vinyl) Alcohol can be made into cryogels with a wide range of mechanical 
properties similar to those of biological tissues. This material is also biocompatible and 
non-biodegradable [30]. A set of experiments were performed on a wide range of 
hydrogels at different PVA concentrations in order to determine the ideal hydrogel that 
would meet the implant’s required properties. The following properties were evaluated 
for the cryogels: moduli of elasticity under compression, tensile strength, tear strength, 
and swellability.  
Manufacturing of PVA cryogel 
PVA cryogel is made through dissolution of high molecular granular PVA in normal 
saline, putting the solution in a mold of the desired shape and putting it through freeze-
thaw cycles. After a few freeze-thaw cycles, the mixture transitions from being a viscous 
liquid to being a solid and the properties tend to plateau at approximately 6 cycles.  
Granular PVA used was obtained from Brenntag under the label selvol 165. The solute is 
mixed with the solvent (water, or saline, depending on the test) in an autoclave-safe 
container, sealed and autoclaved at [insert temp] for 25 minutes. The following formula 
and table prescribe the amount of PVA to use per weight concentration:  
𝑃𝑉𝐴 𝑔𝑟𝑎𝑚𝑠 =   
%𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ∗ (𝑚𝑎𝑠𝑠  𝑜𝑓  𝑠𝑜𝑙𝑢𝑡𝑒 − 𝐻!𝑂,𝑁𝑜𝑟𝑚𝑎𝑙  𝑆𝑎𝑙𝑖𝑛𝑒, 𝑒𝑡𝑐)
1− %𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛    
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Table 10: Amount of PVA to use per 100 mL of H20 for selected concentrations  









After the PVA has been dissolved, the solution is poured/injected into the designated 
mold. It is important to make sure that there are no air voids/bubbles in the solution by 
letting the air rise to maintain the integrity of the parts being manufactured. The mold is 
then put in a freezer start the freeze-thaw process. Putting the hydrogels through freeze-
thaw cycles increases its crosslinking, thus increasing its elastic modulus. When the 
hydrogel is completely frozen, it has a white coloration and is completely opaque. It is 
then thawed at room temperature. Thawed hydrogels are clear and somewhat cloudy. 
Once the first freeze-thaw cycle is completed, the mold is placed back into the freezer. 
For this research, the samples are put through 6 freeze-thaw cycles because this is the 




















4.2 Mold Fabrication  
Multi-part acrylic molds were used for objects of more convoluted shapes that could not 
me created by book molding. This type of mold was used mainly for the cleft palate 
project. Based on the shape and size of each part of the product, acrylic sheets of different 
thickness were sourced from a local manufacturer, McMaster Carr. Each geometrical 
aspect of the product was drawn in AutoCAD and used to laser-cut the different pieces of 



















Figure 9: Example of pre-designed acrylic multi-part mold for naso-oral valve/obturator 
 
4.3 Concept Evolution  
Concept 1 
The problems identified with the current methods of treatment of cleft palate patients 
were the main factors that shaped the bourgeoning of the original concept. As a 
pediatrician, being able to insert a valve-like device that would cover the cleft and 
impeach naso-oral communication, leading to better feeding and sound production, while 
delaying the surgical procedure in order to allow optimal longitudinal palatal growth 
would be ideal both in terms of cost efficiency, and improvement of patient care. This 
original concept involved two thin 2mm flaps joined by a bridge that would be of the 
thickness of the hard palate. The superior flap would fold and lay atop the hard palate, the 

















Figure 10: Concept 1: simple valve-like obturator for cleft palate patient (numbers in mm 
to 2 significant figures)  
 
Concept 2:  
Because of the varying anatomy of clefts based on their nature, changes were made to the 
original concept, adjusting the shape and dimensions of the bridge aimed to fit into the 
cleft. Data of dimensions of maxillofacial anatomy was obtained from past studies 
observing unilateral complete cleft lip and palate and incomplete cleft palate. An anterior 

























































Figure 11: Concept 2: specific valve-like obturator for patients presenting an incomplete 
















Figure 12: Concept 2: Specific valve-like obturator for patients presenting a complete, 













































































































































Figure 15: example of lab-fabricated PVA palatal obturator (sample cut out manually 
with surgical scissors, hence ragged edge) 
  
Concept 3:  
After consulting a few clinicians, it was noted that a major anatomical concern with the 
previous concept was the presence of the nasal septum, a cartilaginous body that lies atop 
the hard palate. Having his would complicate the insertion of the valve, and the designed 
needed to take it into consideration. The superior flap of the valve was thus divided into 
two parts. This made the fabrication of the design even more convoluted. A more uniform 
design for this stage was to have a single flap with two posterior nodules between which 





















Figure 16: Concept 3: Uniform valve-like oburator with nodules (dimensions in mm, to 2 













Figure 17: Concept 3: specific valve-like obturator for patients with unilateral cleft palate 



































































































Concept 4:  
 One of the major concerns from clinicians with the idea of the valve-like device 
was the risk of the patient accidentally aspirating the device, which could potentially lead 
to airway obstruction, and death in the worst-case scenario. Thoughts of sewing the flaps 
onto the soft palate, but because anesthesia would be required for this, the clinicians’ 
preference is to simply operate on the patient and aim for palatal closure. However, 
because it is still a priority to delay the surgery on the palate until it has reached its 
optimal size, the clinicians’ recommendations were to rather address velopharyngeal 
insufficiency, one of the main consequences of a cleft palate, and the discomfort caused 
by the current patient-specific acrylic palatal obturators.  
This stage divided the project into two different products: a pharyngeal wall implant and 
a de novo palatal obturator.  
The pharyngeal wall implant is designed as a block of PVA hydrogel with the elasticity 
of surrounding tissue (0.5-50kPa)[32] that can be carved by the surgeon based on the size 
of the velopharyngeal gap. Similarly, the palatal obturator’s posterior acrylic part is to be 
replaced by PVA hydrogel. The softness and elasticity of this part would have a cushion-
like effect on the cleft, an improvement from the current discomfort caused by acrylic. 
The different part of the obturator are held together by metal pins/wire, and because of 
PVA’s softness, the posterior, U-shaped part of the metal wire would be threaded to 
enhance PVA-Metal adhesion after molding, and reduce the chances of the posterior part 
detaching from the obturator This block of PVA attached to the metal piece would be 
























4.4 Concept Selection 
 
The selection of the final concept to address the problems this research aims to tackle was 
made using the following criteria: ease of fabrication, ease of implementation, likelihood 
of function without too high of a risk based on the recommendation of the surgeons 
consulted. The table below ranks each concept per category. The concept with the highest 












Likelihood to function 




1 1 3 1 4 
Concept 
2 2 2 1 5 
Concept 
3  3 2 1 6 
Concept 
4 5 5 5 15 
 
The table above shows a progression with each new iteration, but also a significant 
improvement with concept 4, which is the final concept being designed for this work.  
It entails, as aforementioned, a velopharyngeal implant to enhance speech production 





Chapter 5: Risk Analysis 
 
5.1 Overview of risk analysis  
 
The risk analysis is an important portion of product development in many industries. 
With medical devices, it is even more important because these devices affect patients’ 
lives through usage. A risk analysis is a mandatory portion of the FDA submission 
process for medical devices, and is very useful because it emphasizes the importance of 
safety of each medical device while indirectly minimizing costs related to potential 
recalls as well as lawsuits.  
ISO 14971, FDA Guidance: Incorporating human factor into risk, FDA guidance: 
Premarketing Risk Assessment are some documents that can be used to draft a device’s 
risk analysis. Identifying risks, evaluating them, determining control methods and re-
evaluating them are the steps to thoroughly follow when drafting a risk analysis. When a 
risk cannot be completely eliminated, it is important to communicate such information to 
the end users, notably the insurance companies, hospitals, physicians and the patients.  
For Class 2 medical devices, the most commonly used approach is the FMEA (failure 
mode effect analysis). The goal with this method is to eliminate failures before they 
occur, and is focused on preventing defects, enhancing safety and increasing customer 
satisfaction. With the FMEA, each function of the device is evaluated and potential 
failure modes are brainstormed. The different effects of each failure modes are listed, and 
each is assigned a number for severity, occurrence and detectability [33]. For certain 
elements, it is not possible to assign a perfect level or occurrence or level of detectability, 
therefore an educated guess is taken. The next step is to calculate the RPN (risk priority 
number) per failure mode effect and prioritize them based on said RPN. Based on the risk 
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analysis rubric, the risks are addressed in order to reduce to RPN to an acceptable 
number.  
Table 12: Detectability grading rubric[33] 
Probability of detection Description Score  
Very Low  
Patient Unaware of product malfunction. 
Trained clinician unable to detect 
malfunction, surgical intervention may be 
required to detect malfunction 5 
Low 
Patient unaware of product malfunction. 
Trained Clinician unlikely to detect 
malfunction without specific technique  4 
Moderate 
Patient unlikely aware of malfunction. 
Clinician may require targeted investigation 
to detect problem 3 
High  
Patient may be aware of malfunction. 
Clinician aware of malfunction following 
routine exam 2 
Very high Patient fully aware of product malfunction 1 
 
 
Table 13: Occurrence grading rubric [33] 
Probability of occurrence  Description Score 
Likely Incidence significantly more than 20%  5 
Probable  Incidence approximately 5-20% 4 
Possible  Incidence approximately 1-5% 3 
Remote  
Incidence less than 1%, occurrence 
contingent upon implant error, patient 
anomaly or unlikely event  2 









Table 14: severity grading rubric[33] 
Severity of failure  Description  Score  
Very High  
Death or serious injury likely without 
prompt medical intervention. Death may be 
imminent  5 
High  
Patient has moderate or chronic clinical 
symptoms in response to decreased 
performance (eg. continued swelling, 
ulcerations, redness, chronic pain) 4 
Moderate  
Patient may present with mild or 
intermittent clinical symptoms indicative of 
slightly reduced performance. Patient safety 
has not been compromised and product 
continues to function in intended manner 
(mild pain, redness, discomfort)  3 
Low  
Clinician may have an isolated test finding 
supporting decreased product performance 
but patient is asymptomatic/Patient may 
claim symptoms without clinical findings  2 
Very Low  
Neither patient safety nor product 















5.2 Pharyngeal Implant Risk Analysis  
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The scores for each potential effect of failure mode based on severity, occurrence and 
detectability were determined after consulting a team of surgeons at Emory University 
School of Medicine Department of Surgery and a team of engineers at Georgia tech.   
Based on the first risk analysis that was done with this device, it was deemed important to 
address the potential failure modes that presented an RPN greater than 15. Those were 
the failure modes that could lead to patient death via airways obstruction or acute 
infection. Requiring appropriate training for the surgeons, designing implant insertion 
and securing method were the main recommended actions that would significantly reduce 
the chances of these failure modes occurring. A second risk analysis was done based on 
these recommended actions, and all RPNs were under 15, which was the goal set for this 
research (see table below). The highest risks after the second risk analysis was performed 
are the following:  
- Implant too large, potentially leading to airway obstruction 
- Incorrect implant orientation/placement, potentially leading to airway obstruction 
- Implant contamination during surgical procedure, potentially leading to infection 
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5.3 Palatal Obturator Risk Analysis 
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Palatal Obturator:  
This is a device that can be removed in a home setting by a caretaker or the patient 
himself. This therefore presents little alarming risk. However, because PVA is 
significantly less elastic than acrylic, there is a chance that the posterior part gets torn or 
slips off the metal anchor, which may lead to aspiration and potentially death via airways 
obstruction, with an RPN of 25. In order to address this risk, the metal anchor used is 
designed to have u-shaped hook in order to create more resistance in case the softer part 
is pulled. This would significantly reduce the occurrences, and lead to an RPN below 15. 
After the risk mitigation, the potential failure modes that present the highest risk are the 
following:  
- Deterioration of the obturator potentially leading to part migration and airway 
obstruction  
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Chapter 6: Verification testing 
 
6.1 Tensile Strength Test 
Experiment protocol  
The tensile strength and tear strength of each hydrogel are particularly important because 
it affects the removability of the implants, a critical design characteristic. The minimum 
tensile strength for each implant was 25 kPa determined experimentally by mimicking the 
action of pulling a sample attached to a load gauge, while the tensile strength of adipose 
tissue between 2 and 24 kPa [34], and is used as a determining parameter. The reason 
why adipose tissue is used as a reference point here is that current pharyngeal 
augmentations are performed by injecting adipose tissue or platelet rich plasma into the 
pharyngeal wall. The samples made (normal saline and 1.8% NaCl in the solution) were 




The tensile strength tests were conducted using an extensometer (Instron materials testing 
machine). Once the dimensions (thickness and width) of the specimens were recorded, 
they were placed into the grips of the extensometer, and the original length of the 
specimens was also recorded. Because the grips are metallic and present a rough texture, 
damage of the specimen may occur so in order to avoid such event, 0.5 mm thin 
cardboard sheets were placed on the outer surfaces of the specimens’ grip ends. The 
specimens were adjusted symmetrically to distribute tension uniformly across the 
sections, and the grip was tightened to prevent slippage. After the specimen is placed into 
the extensometer’s grips, the test is launched using the software supporting the 
extensometer.  The specimen is pulled until it breaks, or tears along the nick in the case 
of the tear strength test. The data recorded by the software includes the load is applied to 
the specimen continuously until yield, the extension of the gauge. This testing apparatus 
software also calculates critical information such as yield stress and maximum strain, 
based on the recorded load and the dimensions originally recorded. For verification 
purposes, the yield stress and maximum stress were calculated manually using the 
recorded loads, dimensions and extension from each test. The tear strength was calculated 
similarly, using the maximum load applied and the thickness of each specimen. All 



































Figure 20: Display of extensometer test for tensile strength 
Stress Equation: 𝜎 =    !
!×!
 
Strain Equation: 𝜀 = !!
!
 
Elongation Equation: 𝐸 =    𝜀!"#×100 




Samples of 1.3%, 2.5%, 5%, 7% and 10% and 20% weight PVA cryogel were tested in 
tension (n=3) to determine each tensile strength.  
The tensile strength is the maximum stress a sample can bear in tension. The values were 
determined by following the ASTM D412-06a standards. The tensile strength of PVA 
samples within this concentration range (4.8-348 kPa) follows an exponential growth 
with respect to the weight percent concentration of polymer in the hydrogel solution. We 
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also compared the tensile strength of hydrogel samples depending on the amount of NaCl 
in the hydrogels, and samples made with 1.8% NaCl have a slightly lower tensile strength 
compared to those made with 0.9% NaCl tensile strength. The minimum tensile strength 
for these samples was set as 25 kPa.  
 
Figure 21: Tensile (top) and tear (bottom) strength test samples (white), following 
ASTM standards.  
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Figure 22: Sample stress-strain curve (20% PVA) 
 
 
Table 19: Tensile strength of PVA samples made with 0.9% and 1.8% saline solution 
(not acceptable in grey: below 25 kPa)  
PVA 
Concentration 
Tensile Strength (kPa) for 
samples with 1.8% saline 
solution 
Tensile Strength (kPa) for samples 
made with 0.9% saline solution 
1.30% N/A 4.8 
2.50% N/A 8.5 
5% 28.33 33 
7.50% 40.7 60.3 
10% 71.3 109 






Figure 23: Tensile strength of PVA samples at different polymer concentrations (made 




	    
Figure 24: Tensile strength of PVA samples made with 0.9% saline and 1.8% Saline 
after freeze-thaw cycles 
y	  =	  1.96e0.8483x	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6.2 Tear Strength Test 
 
Experiment	  protocol	  	  
 
The tear strength tests were performed following the ASTM D624-00 (Die B) protocol. 
Specific molds were manufactured out of acrylic, yielding dog-bone shaped samples.  
The tear strength tests were performed following the ASTM D624-00 (Die B) protocol.  
The acrylic mold manufactured for the tear strength tests yielded zig-zag shaped samples, 
per the standard prescription. Specifically for the tear strength test, a 1mm nick was made 
at the peak of each specimen’s curvature. The samples made (normal saline and 1.8% 
saline) were tested immediately after 6 freeze-thaw cycles, and without any drying. 
Similarly to the tensile strength tests, the tear strength tests were performed using the 
Instron materials testing machine. The differences between the tear strength test and the 
tensile strength test protocols are the shape of the sample (see figure 20) as well as the 
data collected from the samples. For the tear strength test, the thickness of the specimens 
is measured with a caliper, before the extensometer pulls the specimen at a rate of 500 
mm/s, and the testing apparatus’ software records the load applied. The load at complete 
break is divided by the specimen’s thickness, and the tear strength of the specimen is 
obtained. 
Tear Strength Equation: 𝑇! =   
!!"#
!
 (t= thickness, Fmax = maximum load)  
Results 
The tear strength was determined following ASTM D 412 standards. It is a good measure 
of how well a material resists the growth of any cut under tension, and as 
aforementioned, is measured in N/mm for this study. We observe an exponential growth 
in tear strength as the weight percent concentration of PVA in the cryogel solution 
increases.  Based on the results below, 5% PVA is more than four times stronger in tear 
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than 1.3%, while 10% PVA is almost 20 times stronger than 1.3%. The tear strength of 
samples of 1.3% and 2.5% PVA are significantly below the acceptability criteria (see 
table 19) whereas samples of 5%. 7.5% and 10% PVA meet this requirement. 
Table 20: Tear Strength of PVA samples made with 0.9% and 1.8% Saline solution (N/A 




Tear Strength (N/mm) for 
samples made with 1.8% 
Saline Solution 
Tear Strength (N/mm) for 
samples made with 0.9% 
Saline Solution  
1.30% N/A 0.24 
2.50% N/A 0.32 
5% 0.789 1.05 
7.50% 1 2.29 
10% 2.23 4.1 














6.3 Compression Test 
Experiment protocol 
The compression test on hydrogels leads to determining the modulus of elasticity of the 
hydrogels at different PVA weight concentrations, in order to best mimic human tissue 
softness. This will help selecting which concentration will give the implants a more 
natural, comfortable feeling. There are different types of tests used to determine the 
softness of materials, and the modulus of elasticity is the most common measure used to 
quantify it. The samples made (normal saline and 1.8% NaCl in the solution) were tested 
immediately after 6 freeze-thaw cycles, and did not undergo any drying or swelling.  
The Instron material testing machine was used to perform the compression test, and the 
specimens tested were obtained by cutting out circle-shaped samples out of thick sheets 
of PVA cryogel cured in flat trays. Once the samples have been cut out, they are 
measured with a caliper (diameter and thickness), placed at the center of a flat support 
sheet (metal), and the head of compression machine is brought to right above the sample. 
The test is then started. Similarly to the tensile test procedure, the software assisting the 
testing apparatus records the load and extension of the gauge. Based on the raw data, the 
strain and stresses are determined, which leads to calculating the modulus of elasticity 



















Figure 26: determining the elastic modulus of a specimen based from the Stress-Strain 
curve  
 
Modulus of Elasticity 
 
The compressive modulus of elasticity is determined by observing the stress-strain curve 
of each sample tested in compression and determining the slope of the region of the curve 
considered to be elastic. The values are averaged per samples to obtain the final modulus 
of elasticity. The compressive elasticity of PVA at different concentrations follows a 
linear growth with a high coefficient of correlation (R = 0.97), increasing with the weight 































Figure 27: Sample stress strain curve for compression test on PVA samples used to 





















Figure 28: Sample stress strain curve for compression test on PVA samples (lower 





Table 21: modulus of elasticity of PVA samples made with 0.9% saline, and projected 
modulus of elasticity of PVA samples made with 1.8% Saline  
Concentration 
Young Modulus kPa 
(samples made with 1.8% 
Saline Solution) 
Young Modulus kPa (samples 
made with normal 0.9% Saline 
Solution) 
1.30% N/A 7.73 
2.50% N/A 11.65 
5% 46.21 51.35 
7.50% 55.04 64 
10% 68.72 80 







Figure 29: Compressive elasticity of PVA samples made with 0.9% saline, acceptable 
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Figure 30: Correlation curve between tensile strength and compressive elastic modulus 































6.4 Durometer Hardness:  
 
 Experiment protocol 
Another tool used to quantify/qualify the softness of the hydrogels in this project was the 
Shore Durometer Type A [36].  Durometers are use to determine the hardness of 
materials, and the type A durometer specifically for soft rubbers and elastomers. The 
durometer’s needled is pressed into the material of a minimum thickness of 6.4 mm for at 
least 15 seconds, and in the case of an electronic durometer, the number appearing on the 
screen is the hardness.   
Results 
 
Figure 31: Shore A durometer hardness per PVA concentration (no difference recorded 
with changes in salt content) 
 
Shore durometer hardness, used to quantify the hardness of soft elastomers was used to 
supplement the elasticity criteria selected as an end point to determine the ideal PVA 
concentration for each implant. On scale A, the hardness of PVA follows a linear growth 
with respect to the polymer concentration in the hydrogel solution.  
 
 
y	  =	  3.4625x	  -­‐	  1.4375	  


























Hydrogels tend to swell when submerged in water. This is an important characteristic 
because the customer (surgeon and patient) would like to know how much swelling to 
expect after the implant has been inserted. Additionally, because water content changes 
the mechanical properties of the hydrogels, the swelling can be used to design the most 
suitable implant. For example, implants of a higher elastic modulus (and PVA content) 
may be easier to insert, but may not feel as natural as needed.  If the implant can swell to 
a level or hydration that can significantly lower its elastic modulus, this may help with 
material selection. One can change the concentration of polymer in an implant by starting 
with a certain concentration, or starting with a lower concentration and drying the product 
after casting.  For example, PVA samples can be made at a set concentration C1, and then 
densifying the sample by drying the samples in an oven at a controlled temperature of 70 
degrees Celcius.   The dried concentration C2 may be calculated by weighing, assuming 
that only water is evaporating.  A target weight can be set, based on the desired 
concentration for the dense sample.  After the dense sample can be placed in either 
normal saline or water.  As the implant absorbs water, it swells.  Swelling is then defined 
as the pre-set water content of the sample was simply based on what concentration of 
PVA yielded the adequate softness for the implants. 
For example, 2.5% PVA samples (water content 97.5%) were dried in the oven 
and progressively weighted until they lost sufficient amounts of water to become 7.5% 
PVA (92.5% water content). After being dried, the samples were submerged in a normal 
saline and then weighted to observe a change in weight.  The measurement is then 
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reported as the increase in weight over time.  The increase in weight is attributed to water 
absorption or an increase in water content. 
Alternatively, one can observe the water increase in samples that are not initial 
dried. The other samples observed in swelling (Swelling B) did not go through the drying 
process, but rather were submerged in normal saline immediately after the freeze-thaw 
cycles, and observed over the course of 48 hours.  




PVA is a hydrophilic polymer, and its cryogels tend to grow in volume when surrounded 
by a hydrated environment. They also shrink in volume when exposed to a dry 
environment.  Few factors affect the swelling of PVA hydrogels, including the osmotic 
pressure and the crosslinking of the hydrogels. It was observed by this study that an 
increased concentration of PVA in the hydrogel solution would lead to more swelling. 
Additionally, more swelling is observed in hypotonic solutions compared to isotonic 
solutions for hydrogels. Swelling is defined as the ratio between the change in weight and 











Dried samples (Swelling A): 
 
After drying 2.5% PVA samples into 7.5% PVA and submerging them in a normal saline 
bath, we observed swelling in the 0.9% material and 1.8% material of approximately 7%. 
  
 
Figure 32:Mass of 7.5% PVA samples over time during swelling A (samples weigh 
respectively 0.3 and 1.31 grams in average)  
 
 
In this experiment, the weight of samples was measured until a plateau (less than 0.2% 
swelling per hour) was reached for each case. Looking at the trend of the increase in 
weight over time appears somewhat misleading, thus the water content of the samples 
was calculated by adding the change in in weight of the sample to the original water 
content and dividing the result by the original sample weight, and plotted in order to 
depict the difference between the two types of samples.  
𝑊𝑎𝑡𝑒𝑟  𝐶𝑜𝑛𝑡𝑒𝑛𝑡 =   !!!!!
!!
×100;  Where Δ𝑤 is the change in weight of the sample, 𝑤! 























7.5%	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  with	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NaCl	  




            
Figure 33: Water content for 7.5% PVA samples made with 1.8% Saline solution and 
0.9% saline solution then placed in normal (0.9%) saline  
 
 
Undried samples (Swelling B): 
Additionally, samples of higher PVA concentration present increasingly more swelling 
(see table and chart below).  
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Table 22: Mass increase from water uptake during swelling for PVA samples after 6 
freeze thaw cycles (Swelling B) from 10% to 40% in isotonic normal saline  
PVA 







Chapter 7: Discussion 
 
7.1 Device description:  
 
This work led to the design of two separate devices: an implant destined to boost the 
pharyngeal wall and shorten the velopharyngeal gap, and a palatal obturator. As 
aforementioned, the pharyngeal wall implant is in the form of a sterile block of PVA that 
the surgeon will be able to carve in order to match the patient’s velopharyngeal anatomy. 
This implant will allow the patient’s speech production to develop normally. 
Additionally, the palatal obturator, designed to have a softer posterior part, is a device 
that will not only help with speech production, but also feeding of the patient. The 
posterior part is currently designed to be a block of PVA attached to the anchoring metal, 
and will also be carved by the physician based on the size, shape and type of cleft the 
patient presents.  
                   
7.2 How the devices addressed the unmet needs 
 
Combining the implantation of the pharyngeal implant and the usage of palatal obturators 
in patients presenting a cleft palate allows the team in charge of treatment to delay the 
palatoplasty, while still having a solution of speech production and feeding. Delaying the 
palatoplasty until the patient is about 5 years old allows optimal maxillofacial growth and 
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reduces chances of other related maxillofacial defects as mentioned above. This implant 
therefore serves as a buffer for the care team. Additionally, the problem of discomfort 
due to the hardness of current acrylic obturator is addressed by selecting a material with 
mechanical properties closer to those of human soft tissue compared to acrylic.  
 
7.3 Comparison with other devices – Competitive Advantage 
Pharyngeal Implant  
The pharyngeal implant is designed to be a block of PVA the surgeon can carve to match 
the size and shape of the velopharyngeal gap. Posterior wall augmentation and 
Pharyngeal flap are the most common surgeries for velopharyngeal insufficiency in cleft 
palate patients. In both surgeries, autologous tissue is commonly used to fill the void[37-
40].  However, in the past, synthetic materials including silicone (silastic), Teflon, 
proplast and collagen were used as implants. These were deemed undesirable in the long 
term due to post-operative complications and FDA restrictions [41, 42]. Porous 
polyethylene, commercialized by Medpor, is mostly used for craniofacial cartilage-like 
implants such as chin, nasal and mallar because of its stiffness. The lining of the 
pharyngeal wall is however soft tissue; therefore, use of a softer material for such 
implants would be better according to the surgeons consulted. Additionally, because of its 
texture, porous PET allows tissue ingrowth and is not favorable for removal in case of 
complications, unlike smooth-textured PVA[43] . The table below compares Medpor’s 
PET mechanical properties to those of PVA hydrogels at concentrations deemed 



















Tissue Growth Recorded 
Implant 
Migrations 
Porous PET (medpor) 227-307 23 45 Yes  Yes 
Silicone 2.07 6.55 1.03 No Yes 
Smooth 5% PVA  5.135×10!! 3.3×10!! 1.05×10!! No N/A 
Smooth 7.5% PVA 6.4×10!! 6.03×10!! 2.29×10!! No N/A 





De Novo Palatal Obturator:  
The current material used for palatal obturators is acrylic. Table 22 shows acrylic’s 
mechanical properties compared to the PVA hydrogels considered for this device  [10%, 
5%, 7.5%], acrylic is of much higher elasticity. Surgeons were surveyed and they suggest 
that a softer material, closer to adipose tissue be used for the posterior part of the 
obturator so that it is more comfortable, less painful for the patients. Therefore, selecting 
a hydrogel that fits within the adipose tissue elasticity range would be a better fit 









Table 24: Comparing Silicone and Acrylic’s mechanical properties with acceptable 
concentrations of PVA hydrogels   
 
Modulus of elasticity (MPa) Tensile Strength (MPa) Tear Strength (kN/mm) 
Acrylic 3.2×10! 75 N/A 
Silicone 2.07 6.55 1.03 
20% PVA 2.×10!! 3.48×10!! 8.67×10!! 
30% PVA 8×10!! 1.09×10!! 4.1×10!! 
 
 
7.4 Limitations  
 
The cleft palate part of this research focused on a preliminary design for both the 
pharyngeal wall implant and the de novo palatal obturator. In the case of the obturator, 
the research does not cover all the different types of obturators, but rather solely the two-
part obturator that are used in patients with incomplete clefts. Additionally, due to time 
constraints, the foreseen step of cadaver testing to determine the most appropriate 
implantation method was not possible for the pharyngeal implant. Additionally, the 
fabrication of both the velopharyngeal implant and cleft palate implant did not follow 
strict guidelines, leaving room for improvement for future work.  
In terms of tests performed on the material to be used, certain tests suggested by the FDA 
for implants were not performed, also due to time and resources constraints. The 
following tests were not performed: cytotoxicity test, sensitization test, 
hemocompatibility, pyrogenicity, genotoxicity, carcinogenicity, and biodegradation. 









Chapter 8: Part 1 Conclusions 
 
It is important to note that with lower the concentration of PVA, the elasticity and tensile 
strength diminish. The tensile strength of PVA at 2.5% weight concentration is 8.5 kPa, 
below that of 5% PVA (33 kPa) as well as the set lower boundary for this criterion, 25 
kPa. Based on this tensile strength criterion and the trendline obtained from the 
experimental tensile strength data, PVA at a percent weight concentration of 3% or above 
would meet this requirement. Lower weight concentrations of PVA (10%) have a 
swelling ratio of 10% or less in isotonic solutions, and said concentrations also meet the 
tear strength criteria of 30 mN/mm. Furthermore, it is important to highlight that PVA 
samples made with twice the amount of NaCl (1.8% Saline solution) show less modulus 
of elasticity, tensile strength and tear strength than similar parts made from 0,9% saline, 
while their swellability is significantly higher. Based on the types of PVA samples tested, 
the ideal weight percent concentration range for the pharyngeal implant would be 5% to 
10% made with normal saline.  
Because of constant removal and insertion of the obturator into the patient’s mouth, it is 
important that the posterior part of the obturator is more elastic than the pharyngeal 
implant. Based on the experimental data and the literature[35], PVA cryogels within the 









Part 2:  Facial implants 
 
Chapter 9: Background 
 
9.1 Market Overview 
 
Over	  the	  past	  10	  years,	  there	  has	  been	  an	  increase	  of	  approximately	  205%	  in	  the	  
number	  of	  soft	  tissue	  fillers	  procedures	  performed	  in	  the	  United	  States	  only,	  
reaching	  a	  high	  of	  2	  million	  procedures.	  Long	  term	  fillers	  (PMMA,	  PLA)	  constituted	  
20%	  of	  the	  total	  number	  of	  procedures,	  while	  HA	  constituted	  75%	  of	  the	  
procedures.	  Having	  to	  get	  HA	  injections	  routinely	  (approximately	  every	  6	  months)	  
can	  become	  an	  inconvenience	  for	  patients,	  but	  the	  current	  long	  term	  fillers	  being	  
irreversible	  confine	  them	  to	  this	  very	  choice.	  In	  2013,	  more	  than	  2.5	  billion	  dollars	  
were	  spent	  on	  injectables,	  with	  nearly	  1.9	  billion	  on	  skin	  rejuvenation.	  Based	  on	  this	  
data,	  the	  potential	  consumer	  base	  for	  the	  facial	  implants	  designed	  is	  about	  500,000	  
procedures	  per	  year.	  The	  table	  below	  shows	  the	  number	  of	  procedures	  performed	  
per	  the	  top	  3	  soft	  tissue	  filling	  injectables.	  
	  
Table 25: Statistics on the number of procedures performed per type of dermal filler in 
2015[44] 	  
Dermal Filler Product Brands  Number of Procedures in 2014 
Hyaluronic Acid  
Juvederm Ultra, Ultra plus, Perlane, 
restylane,Bellotero,Voluma 1,697,621 
Poly-L-Lactic Acid  Sculptra 53,159 









Consumer identification  
The primary consumers for the facial implants are the end users: the patient and the 
health care practitioner that will handle the implantation. The figure below shows a 
distribution of dermal fillers procedures per age groups. Patients 40 years and older are 








Figure 35: Age distribution of procedures involving soft tissue fillers [44] 
 
9.2 Overview of facial implants and soft tissue fillers 
 
Facial implants are solid, biocompatible implants that are specially formed to enhance a 
patient’s facial structure based on their needs. The most popular facial implant 
procedures are malar augmentations, mentoplasties, and lip augmentations. 
There are however, less invasive, non-surgical procedures that pertain to enhancing facial 
features, mainly to restore youthfulness. Dermal fillers are injectables that remove 
wrinkles, soften facial creases and enhance the youthful aspect of the face. Figure 31 
depicts the different facial sites typically candidates for dermal fillers. According the 
American Society of Plastic Surgeons, softer tissue fillers are mostly used for lip 
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plumping, perioral, nasolabial folds and worry lines, while harder materials are used for 
cheek and chin augmentations[44]. 
 Hyaluronic acid (HA), calcium hydroxyapatite (CaHa), poly-L-lactic acid and collagen 
are the main temporary wrinkle fillers, while Polymethylmethacrylate (PMMA) and 
Polylactic Acid (PLA) are semi-permanent (removable) wrinkle filler in the form of 
microspheres. [45-47] 
 Hyaluronic acid is found in the extra cellular matrix and is naturally absorbed [48] 
by the body 6 to 9 months after the injection, and calcium hydroxyapatite is naturally 
found in the bone matrix as well as in the teeth. CaHa microsphere start degrading 9 to 11 
months after injection. PMMA is a more permanent solution; composed of 20% PMMA 
microspheres and 80% collagen [49-51]. These fillers are used to smooth wrinkles, 
correct folds and volume losses. PLA for example was cleared by the FDA for restoration 
of volume for HIV patients suffering from fat loss (lipoatrophy) [52]. Although the long-
term dermal fillers lessen the patients’ “injection fatigue,” these fillers are not removable, 






















Figure 38: Lip plumping result with existing products 
 
 
9.3 Existing products 
 
The main softer tissue filler volume augmentation of the face are collagen, fat, Calcium 
Hydroxylapatite (CaHa), Hyaluronic Acid, Poly-L-Lactic Acid (PLA), Poly(Methyl 
Metacrylate). Additionally, the products used for solid implants include silicone, 
expanded Polyetrafluoroethylene (ePTFE, Gore-Tex) and porous polyethylene (PET), 












Table 26: Recently issued patents by USPTO involving soft tissue fillers [35] 
PAT. 
NO. Title Inventors Date of issue 
8,932,637 
Injectable and swellable microspheres for tissue 
bulking Vogel et al. 1/13/2015 
8,889,123 Compositions and soft tissue replacement methods 
Van Epps et 
al 11/18/2014 
8,846,094 Peripherally administered viscous formulations Lyons et al 9/30/2014 
8,822,676 Hyaluronic acid-based gels including lidocaine 
Lebreton; 
Pierre F. 9/2/2014 
8,815,228 










Injection device for soft-tissue augmentation 
fillers, bioactive agents and other biocompatible 
materials in liquid or gel form Mudd et al. 8/12/2014 
8,795,694 Microparticles comprising PCL and uses thereof Super et al. 8/5/2014 
8,865,879 Chitosan beads and filler comprising such beads kiehm et al 10/21/2014 
8,778,333 Injectable microspheres for tissue construction Vogel et al. 7/15/2014 
8,853,184 
Polysaccharide gel formulation having increased 
longevity 
Strompoulis 
et al. 10/7/2014 
 
Hyaluronic acid ((C14H21NO11)n) is the most popular soft tissue filler, also labeled as 
dermal filler. HA is a chemical naturally found in the extra-cellular matrix, with a half-
life of approximately 1-2 days. For that reason, HA[53] has been crosslinked with various 
chemicals to increase its longevity to approximately six months. HA lasts relatively 
longer in areas surrounded by less muscle than others, such as under the eyes (ie 
periorbital lines, tear through) and less in areas such as the lips. HA has been deemed safe 
for facial injections, and is currently commercialized under 4 FDA approved brand 
names: Restylane, Juvederm, Hylaform and Elevess. [44] 
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Collagen fillers are derived either from human skin or animal skin (bovine or porcine). 
Human-derived collagen formulas are commercialized under a few brands, including 
Cosmoplast and Cosmoderm. Zyderm and zyplast are brands of purified bovine collagen, 
while Evolence is derived from porcine fat. Animal-derived collagen must be tested for 
potential allergy reaction prior to injection. Artefill, a hybrid form of bovine collagen 
mixed with PMMA comes in the form of injectable microspheres.  Because the body 
reabsorbs the injected collagen, the innovative part of Artefill is that the microspheres 
stimulate collagen production. [54] 
Calcium Hydroxylapatite (Ca5(PO4)3(OH) is the heaviest of all dermal fillers. It is often 
used to correct moderate to severe creases such as the nasolabial fold and frown lines. 
Calcium Hydroxylapatite is biosynthetically produced, thus the risk of allergic reaction is 
lower compared to animal-derived collagen because it contains no animal byproducts. 
[47, 50, 55] 
Poly L Lactic acid (PLA) is a synthetic material injected in the face leading to collagen 
production. It is a biodegradable material that was previously used for suturing. This is 
injected in the deep dermis with a special technique called tunneling. Even distribution of 
the PLA is important to avoid the formation of granulomas and potential inflammation. 
The only FDA-approved brand of PLA is Sculptra Aesthetic.[47] 
Polymethyl-methacrylate (PMMA) is made of approximately 20% PMMA microspheres 
and 80% collagen gel. Once the initial collagen is broken down, the PMMA makes the 
body produce collagen in the target area to fill the space under the skin. Because PMMA 
injections are long term, surgeons tend to underfill the void during the first injection and 
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progressively fill it over a series of injections.. The only FDA approved PMMA brand is 
Artefill.  
9.4 Deficiencies that need to be addressed 
The main problem being targeted by this work in the plastics area is the lack of long term, 
removable facial implants for soft tissue fillers. This problem needs to be addressed 
because currently commercialized longer-term soft tissue fillers are not removable, 
giving very little room for correction to the surgeons after insertion. This work therefore 
addresses this by designing sufficiently soft implants for nasolabial folds and lip 

















Chapter 10: Design considerations 
 
10.1 Customer needs  
The table below describes the patient and the surgeons’ needs.  
Table 27: Customer needs for facial implants   
 
Patient needs  
1 To fill targeted facial void/crease 
2 Long life of device (2+ years)* 
 3 Reduce additional surgeries* 
4 Enhances targeted feature/rejuvenates targeted feature*  
 
Surgeon Need 
1 Reduce risk of treatment using device compared to current treatment*  
2 Wide range of device size to select from  
3 Standardized method for selection of size* 
4 Device that is tactile  
5 Minimal number of incisions* 
5 Diagrams and procedures for best practice of positioning, delivering and implanting  
* - Would like to have: The main goal of this work is to design a long term removable 
implant, and the other needs are additional needs that will give the product an edge over 













10.2 Linking requirements to parameters 
After determining the patients and surgeon needs, a QFD was effectuated to translate said 
needs into technical criteria that would then be defined as design inputs.  
Table 28: QFD for facial implants 
 
Design Inputs 




















































































Minimal number of 
incisions  
           
* 
Implantation causes 
minimal local trauma 
 
* * * 
       
* 
Safe device 
      
* * * * 
  Wide range of device size 
to select from 
    
* * 
      Standardized method for 
selection of size 
 
* * * * * 
      Functionality after 
Implantation  
            
Enhances targeted feature * * * * * * 
      
Long life of device * 
      
* * * 
  
Verification Tests  1 - - - - - - - 2 3 4 5 
 
Table 29: Different tests used to verify the implants’ design inputs  
Test Type 
1 Compression Test 
2 Tensile Strength Test  
3 Tear Strength Test 
4 Swelling Test 






10.3 Design Inputs 
The most critical design specifications for these devices are encompassed by the 
geometric characteristics, the mechanical property, and sterility.  The tables below break 
every design characteristic into specific items and outlines to boundary for each.  
 
Table 30: Design Inputs for Facial Implants 
Item  Design Parameter  Design Specification  
A Elasticity 
The material used for the facial implants fold implant should 
have a modulus of elasticity less than 55 kPa  
B Shape 
The facial implant's shape ranges between being a truncated 
cone and cylindrical, with an ellipse as the base  
C Insertability 
Implant easily insertable not only by surgeons, but also 
dermatologists  
D Size of superior end The superior end of the implant must be no wider than 6mm 
E Size of inferior end 
The inferior end/tip of the implant must be at least 2mm wide, 
and no wider than 4mm** 
F Length  The length should range from 25 to 50 mm** 
G Volume 
The volume of the nasolabial fold implant could range from 
0.25 to 5 mL** 
H Biocompatibility The implant meets ISO 10993 requirements for implants  
I Removability 
Remains intact and solid, does neither dissolve nor degrade in 
physiological conditions 
J Tensile Strength The implant should have a tensile strength of at least 0.5 N   
K Tear Strength The implant  should have a tear strength of at least 0.5 N  
L Swellability 
Implant must neither swell by more than 20%, nor shrink in 
physiological conditions 








10.4 Justification of Design Inputs 
• Elasticity – For this work, one of our main goals is to make solid, removable 
implants that would still feel natural to the patient and not cause any discomfort. 
In order for this to be attained, the implant’s modulus of elasticity must fit within 
the adipose to skeletal muscle tissue range of elasticity: 0.05 kPa-50 kPa[32]  
• Shape – samples of the cylindrical/truncated cone shapes gave the targeted 
features (nasolabial fold and lips) a very natural, yet enhanced look.  
• Volume – the recommendations for current volume fillers indicate no more than 5 
ccs per treatment for nasolabial folds and lip implants, hence 5 ccs being the 
upper limit of implant volume  
•  Superior and inferior ends – The inferior end of the implant must be wider than 
2mm because the wider tip lessens the chances of the implant bending/curling 
once implanted. On the other hand, the superior tip must be less than 6mm wide 
because one of the surgical goals is to keep the incision for the insertion as small 
as possible.  
• Tensile and Tear Strength – both were determined experimentally by pulling a 
sample implant from an extensometer using surgical forceps and recording the 
load (0.5 N per pull). This was necessary because it is part of the criteria covered 
by the removability of the implant.  
• Removability - in order for the implants to be fully removable, they must not 
deteriorate under temperatures the body may be exposed to (stay intact up at 
degrees Celsius) not break/tear under stress due to facial movements 
• Asepticity/Sterility – the implants must be sterile when inserted into the patient 
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• Biocompatibility – The implant must be compatible with the human body in 
order to reduce risks of immune reaction or lead to dangerous consequences such 
as development of cancerous cells               
Chapter 11: Concept development 
 
11.1 Material Selection  
 
As the need for a volume filling implant in this design was similar to that of the 
pharyngeal implant for cleft palate patients, the same material, Polyvinyl Alcohol was 
selected. The wide range of mechanical properties, biocompatibility and non-
biodegradability as well as its proven longevity in the human body [30] are factors that 
influenced this material selection. 
11.2 Mold Fabrication 
For a large portion of this project, 3D printed 2-part book molds were used to create parts 
for testing. The two parts of a book mold fit into each other through a male-female, and 
once pulled apart after curing, the object obtained is of the image of the mold’s crevices. 
In order to obtain the 3D printed molds, the product aimed to fabricate was first drawn 
using a CAD software (Autodesk inventor). From the CAD file of the object, a negative 
mold is derived and spit the longitudinal plane of the object. This mold CAD file is 
exported into a mesh file (STL), and processed through the 3D printer’s software: 













Figure 39: Examples of 3D printed mold (half) for nasolabial fold implant 
11.3 Concept evolution 
Concept 1: separate designs for nasolabial fold and lip implant:  
The first concept design for the facial implants was mostly based on the shape of the 
features aimed at for correction or enhancement. For the nasolabial fold, the design 
involved a triangular prism that would reduce the depth of the crease due to its shape. 
This prism was aimed to be produced in a generic size and adjusted in length and width 
by the surgeon based on the length and depth of the patient’s nasolabial fold. 
For the lip implant, the design was more complex because of the shape of the upper lip. 
This design was made by connecting smoothly two cone-like solids with a thinner cupid 
bow, per the anatomy of the human lip. See figure 36. 
The prototypes for both implants were made by injecting PVA hydrogel solution into 
each implant’s respective, two-part mold 3D printed PLA molds and putting them 
through 6 freeze-thaw cycles. After the last freeze-thaw cycle, the implants were 
carefully removed from the molds and the flash lines (extra material due to book 
molding) were cut out using surgical scissors. The same method creating the implants by 




Figure 40: Design of lip implant (concept 1) (numbers in mm) 
 
Concept 2: Simple Cone for nasolabial fold and Lip Implants 
The second concept was influenced by the need to lessen the number of incisions made 
during the insertion of the implants, therefore limiting it to only one. This meant splitting 
the lip implant into two symmetrical components that would be inserted from the 
midpoint of the inner midpoint of the Cupid’s bow. This trend of thought lead to 
designing a cone that would be used for both the lips and the nasolabial fold with varying 










































for the nasolabial fold as well because the depth of the crease tends to diminish with 
inferior progression from the alarfacial groove. 
Figure 41: Image of conical PVA implants post removal from mold with flash material 










Concept 3:  
The third concept was influenced by the need to secure the implants once inserted in 
order to keep it from moving, as implant migration is one of the major concerns with 
solid implants. In order to address this, a loop was added at the base of the cone (previous 
design). The purpose of the loop was for it to be sutured into the skin, and to also allow 
seamless removal, should it be necessary after insertion of the implant.  After testing, it 
was found that the loop was not needed because of the implant’s surface smoothness and 
the way it fit into the dilated pocket made removal easy reducing chances of migration, 
which is a concern with many of the current implants and dermal fillers [56-58].  
Figure 42: Concept 3- Design of facial implant with removal loop  (dimensions in mm, 

















































Concept 4:  
After a few experiments, it was determined that disrupting the fibrous tissues that connect 
the skin and the facial muscle in the case of the nasolabial fold had a stronger effect on 
reducing the depth of the fold than inserting the implant itself, therefore, the implant for 
the nasolabial fold, although kept at a conical shape, was designed to be flatter serve as a 
placeholder to prevent more fibers to connect the skin and the facial muscles. The lip 
implant on the other hand, still serves as a plumping agent and keeps the conical, volume-
filling shape. The Implants also have a 1 mm centric channel that allows insertion with a 
specifically designed pin. With this final concept, the loop at the base of the implants no 
longer is.  
Figure 43: Concept 4 – flattened cone design for nasolabial fold implant (dimensions in 








































































































11.4 Concept selection 
In order to determine which concept was the most ideal for the soft tissue filling implants 
being designed, a few criteria were considered: ease of implantation, ease of fabrication, 
and enhancement of targeted feature. The table below shows each concept and its score 
based on the aforementioned criteria.  
Table 31: Comparison of different concepts for the facial implants 
 
Ease of implantation Ease of fabrication Enhancement of targeted feature Product  
Concept 1 1 1 4 4 
Concept 2 2 4 5 40 
Concept 3  3 4 5 60 
Concept 4 5 5 5 125 
 
The latest concept (concept 4) is easier to implant and fabricate because of the nature of 
the respective molds as well as the way each implant respectively fits the volume filling 
purpose. The nasolabial implant, because of its flatter nature is easier to insert after the 
pocket has been created rather serves as a solid that keeps the disrupted fibrous tissue 
from connecting the skin and the facial muscle tissue, while the lip implant has a more 










11.5 Implantation Mode 
Through this research, an emphasis was placed on making sure that the implants designed 
would be easily implanted not only by surgeons, but also dermatologists in order to 
increase the throughput of potential users. Although in vivo work is an important part of 
product development in medical devices, using similar methods in cadavers sufficed to 
determine the best method of insertion.  The different cadaver testing iterations made it 
possible to tweak the design concepts for the best possible fit. The first step in cadaver 
testing was making a small incision (2mm) and using a surgical dilator to create a 
subcutaneous pocket for the implants. Although it was possible to insert the implant after 
having created a pocket with a smooth-surfaced dilator, it was difficult to do so partly 
because of the nature of the tissue. The surgical dilators’ inability to create appropriate 
pockets lead to using screws as dilators because of their ability to disrupt different types 
of fibers.  Different types of screws were used (thread height, spacing, etc) and all were 
able to create a pocket for the implant.  This important finding helped designing the 
insertion kit for the implants.  
 





11.6 Insertion Kit design  
Dilator 
 Because of concerns such as level of trauma post-surgery, the screws’ characteristics 
such as threat height, sharpness of the threads and nature of the tip (blunt vs punctilious) 
were taken into consideration when designing an implant-specific medical-grade screw. 
The number of threads on the screw was also considered important because one of the 
primary goals of this design is to make the insertion of the implants as simple as possible 
for the surgeons and dermatologists.  The number of threads per dilator would impact the 
dilation time but also the effectiveness in fiber disruption.  The goal with this dilator is to 
create a pocket of a similar shape and to that of the implant with a buffer amount of space 
to reduce potential pressure on the implant. The dilator’s design went through two 
iterations.  
The first set of dilators was designed by adding threads similar to those of an industrial 
wood screw to the original CAD design of the implant. Two dilators were designed, one 
with a total of 10 threads and another one with a total of 5 threads. See figure 43 and 44. 
A surgeon on a cadaver subsequently tested the dilators; he was able to create a pocket 
with both dilators, however he found that less spacing between the threads was better. 
Another important point from this test was that it was neither necessary for the dilator to 
be threaded from the tip to the base, but rather only halfway through its shaft, nor was it 
imperative for the dilator’s basal half to be conical, or of the shape of the implant. The 
basal half of the implant could simply be cylindrical, similarly to self-taping screws and 
flat-headed screws. These findings lead to a second iteration for the dilator’s design, 






















Figure 45: Different designs of dilators for the implant pocket (5 threads, half of the 

























































































































Figure 46: Examples of 3D Printed Dilators for implant pockets 
Placeholder:  
The placeholder is a plastic solid, in the shape of the implant used to keep the tissue from 
collapsing on itself after the pocket has been created using the dilator, while the surgeon 
prepares the implant for insertion.   
Implant Inserter:  
Keeping the implant sterile during the insertion is a very important part of the procedure; 
therefore it was deemed important to create an inserter that would not only make the 
implantation simple, but also shield the implant from potential contact with the external 
environment. This inserter consists of a 1 mm plastic/metal pin that fits in the implant’s 
channel, a ball-like handle and a plastic sleeve with a flange on the implant end. Once the 
implant is inserted into the pre-dilated pocket, the surgeon/dermatologist would apply a 
small amount of pressure on the sleeve for the flange to press against the patient’s skin, 
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while pulling the pin out by its ball-like handle. The surgeon/dermatologist would then 


























Figure 48: Design of implant needle, meant to fit into the inserter (dimensions in mm, to 































































Chapter 12: Risk Analysis 
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The majority of risks involved with potential failure modes of facial implants are 
cosmetic, and not likely to lead to patient death. These include implant migration, 
distortion, and shrinkage.  The level of severity, occurrence and detectability for each risk 
was determined based on the aforementioned grading rubrics and consulting a team of 
engineers as well as two surgeons. More dangerous failure modes such as infection may 
occur, however, due to the combined low occurrence and severity, the RPN for this 
potential failure mode is below 15. With proper pre-insertion care from the surgeon, these 
facial implants present low risk for the patient.  
 
Chapter 13: Verification testing 
 
13.1 Material Properties tests  
The following tests were performed to demonstrate the design inputs and risk mitigations:  
- Compression Test  
- Swelling Test  
For tests above, please refer to Part I, 
- Tensile Strength and Tear Strength:  
From part 1, the material properties were determined, and based on the tensile strength of 
each type of PVA, we determined the tensile strength of the implants in terms of force.  
The average cross-sectional area of the implant was determined to be 51.5 mm2  and the 
average thickness 5.18 mm. the cross sectional area and the thickness of the implant were 
respectively multiplied my the tensile strength in Pascals and N/mm, and these were then 
determined specifically for the implants. The table below displays both the tensile 




Table 33: Tensile and Tear strength of the facial implants (PVA samples with Normal 
Saline) Both the minimum tensile strength and tear strength were set at 0.5 N.  
PVA Concentration Tensile Strength (N) Tear Strength (N) 
1.30% 0.25 1.28 
2.50% 0.45 2.27 
5% 1.7 8.80 
7.50% 3.10 16.1 
10% 5.60 29.1 
 
13.2 Cadaver Insertion Test 
 
The cadaver tests were performed to verify the insertability of the implants designed. 
Three iterations were effectuated in order to each time better the insertion method, and 
this also led to the design of the implant insertion tool kit.  
During the first test, a small incision (1mm) was made using a surgical scalpel, and a 
channel for the implant was created using a surgical dilator. Inserting the implant into 
said channel proved itself to be difficult and required two to three iterations prior to 
succeeding because of the tissue collapsing on itself.  
 
 
Figure 49: Left: Incision made with scalpel pre implant insertion, Right: Surgical dilator 







During the second test, industrial metal screws and bolts were used to dilate the implant 




















Figure 50: Set of industrial screws used for cadaver testing (dilation of implant pocket)  
 
 



































Chapter 14: Discussion 
 
14.1 How the device addressed the unmet needs 
 
The facial implants designed through this work for the nasolabial fold and lip implant are 
novel in the sense that, unlike the current devices commercialized and used as dermal 
fillers, they are removable solids involving less risks and potential complications, and are 
also long term implants because of the non-biodegradability of the material selected, 
PVA cryogel.  
 
14.2 Comparison with other devices – Competitive Advantage 
 
For facial implants, the FDA recommends a set of criteria to be met with respect to the 
following material properties: Tensile strength, tear strength, yield elongation and 
modulus of elasticity. It can be argued in the case of our research however; that 
elongation is not an important criterion because of the type of interaction the implants 
designed will have with their respective surroundings. The more important criteria from 
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the list above are the modulus of elasticity, a quantitative description of material softness, 
the tensile strength and lastly the tear strength.   
Mechanical properties of popular biomaterials used for facial implants were surveyed and 
listed for reference in table 31. PET, ePTFE and silicone are the most popular 
biomaterials used for facial implants.  
Table 34: Mechanical properties of popular polymeric materials used in facial implants  
 
Modulus of elasticity (MPa) Tensile Strength Tear Strength (kN/mm) 
Polyetrafloryethylene  
(Gore-Tex) 
6 12 179 
porous PolyEthylene (medpor) 227-307 23 45 
Silicone  2.07 6.55 1.03 
PMMA 1800-3100 47-79 N/A 
 
Modulus of Elasticity:  
The modulus of elasticity is the most important mechanical property when it comes to 
facial implants because the softness or hardness of the implant, depending on the feature 
being enhanced has a tremendous impact on whether the implant feels natural to the 
patient, while maintaining the intended shape. It was found in the literature that the 
modulus of elasticity of adipose tissue ranges from .5 to 50 kPa, [32]with subcutaneous 
adipose tissue being the softest and omental adipose tissue being the most elastic. 
Meanwhile, skeletal muscle tissue’s elasticity ranges from 21.2 to 28.2 kPa at the passive 
state [59]. PVA weight percent concentrations between 1% and 5% fit within the range of 
adipose tissue elasticity. PMMA for example, common soft tissue filler, is known to have 
an elasticity ranging from 1800 to 3100 MPa [35]. PMMA’s elasticity is significantly 
higher than that of the surrounding soft tissues in the case of dermal fillers, making it too 




Tensile Strength:  
Because the majority of current soft tissue volume fillers are injectable microspheres, 
they are neither removable, nor are they tested in tension. Tensile strength is an important 
criterion for the design of these implants as it translates into their removabilty. An 
estimate of the load applied to the implants under tension during removal was obtained 
by measuring the load applied to implants clamped to an extensometer while pulling the 
implant using surgical forceps, mimicking the action of pulling the implant out of its 
pocket. Based on experimental data (table 18) PVA weight percent concentration of 5,7.5 
and 10% meet the 0.5 N minimum tensile strength. Using the exponential trendline 
obtained from the data, a minimum PVA weight percent concentration of 3% is required 
to meet the 0.5 N minimum tensile strength.  
Tear Strength:  
The minimum tear strength for soft tissue volume filling implants was also determined 
experimentally, Using the same estimate of load from tension and dividing it by the 
average thickness of the implant. This yielded a tear strength of 0.5 N, which is met by 
samples of concentrations 2.5% and above. 
Durometer Hardness:  
Durometer hardness is a criterion suggested by the FDA for implants fabricated with 
rubbery materials . This is tested following ASTM D2240 standards. The shore A scale, 
typically used for soft rubbers was selected to test these implants. However, because the 
results being on the lower end of the scale, it was determined that for future reference, the 
lower scale “00” would be more adequate. The company Nusil Technology has 
developed an ultra soft low consistency silicon elastomer MED 4286, intended for soft 
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tissue implants, and this material has a shore 000 hardness of 55, and a tensile strength of 
45 psi (310 kPa)[60]. Certain studies have also studied the correlation between Shore A 
hardness and modulus of elasticity, and come up with empirical equations relating the 
two variables. The table below compares the expected hardness for each concentration 
based on the experimentally obtained elasticity:  
Table 35: Comparison of expected durometer hardness based on elasticity and 






1.3%  N/A 3 
2.5% [1.1,1.9] 4 
5% [5.6,6.9] 8 
7.50% [8.15,9.85] 9 
10% [11.27,12.97] 10 
 
After performing a T-test to determine whether the expected hardness was within the 
95% confidence interval of each experimental value, it was determined that only 7.5% 
PVA values matched those. The variations and differences here can be attributed to the 
error from manual calculation of the elasticity of each hydrogel specimen.  
Hydrogel Swelling:  
Based on experimental data, it is observed that PVA hydrogels made with higher polymer 
concentration in the solution swell more over time. The maximum swelling vs weight 
percent concentration curve is a linear curve. It was observed that samples of lower 
concentration reach their swelling plateau  (less than 0.2% swelling per hour) at 
approximately 10% of swelling. Additionally, a change in the solute used to make the 
hydrogel significantly affects the swelling of the specimens. Doubling the amount of 
Sodium Chloride in the hydrogel to 1.8%, making the swelling experiment a hypotonic 
solution increases the amount of swelling for the specimens. Both trends concur with data 
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in previous studies where the change in osmotic pressure affects the nature of the 
hydrogels’ swelling, and hydrogels of higher polymer content swell significantly more 
than those of lesser polymer content [61].  
 
Design of Implants and Insertion Method 
Dermal fillers are shapeless injectables, and meant to simply fill the spaces in which they 
are inserted. However, the design of these implants can be compared to that of Gore-Tex 
and ADVANTA ePTFE implants. Gore-Tex and Advanta implants are noodle-like 
cylindrical tubes of ePTFE, consisting of two layers of the material at different levels of 
porosity. The shape and size of the implants impact the insertion procedure. For example, 
the ePTFE implants used for lip plumping are the full length of the patient’s lip, and the 
insertion method involved making two incisions, at both extremities of the lip in order to 
thread the implant from one extremity to the other [62, 63]. The facial implants designed 
for this research allow a simpler insertion method by reducing the number of incisions to 
just one mid-lip incision is made in a way that each implant can be inserted towards both 
extremities of the lip using the special dilator and inserter.  Likewise, the insertion of the 
implant into the nasolabial bold only requires one incision instead of two like that of the 
ePTFE implants. Another important aspect of the insertion method of these implants is 
that the threading of the dilator allows for a safety net that prevents potential puncturing 
of the facial artery, which is an occurrence with injection of common dermal fillers. 
Injection fatigue also being a problem with dermal fillers such as HA due to the recurrent 







The mechanical properties of the hydrogel are determined by following ASTM standards 
and methods used in previous research studies. For Tensile and Tear strength, the ASTM 
D638 and D624 standards were followed with a slight deviation. However, the 
extensometer used did not have auto-tightening grips, so the samples were clamped 
manually.   
Additionally, it was noticed during experimentation that if not tested immediately after 
taken out of the mold, samples tend to lose some of their water content most likely due to 
gravity. This concern was addressed but once the samples were made, the potential water 
losses during the freeze-thawing process were not accounted for. Additionally, the 
swelling experiment that was performed did not account for technicalities such as the 
ratio between the volume of the bath and the volume of the hydrogel samples being 
submerged, as done in other studies observing swelling of hydrogels which could have 
affected the swelling ratio of the samples.  
Certain mechanical tests were not performed such as creep, wear, and cyclic loading for 
fatigue because we do not expect the implants to be subjected to high enough loads that 









Chapter 15: Part 2 Conclusions 
 
Based on the data obtained from mechanical testing and the preemptively set boundaries, 
it can be concluded that the ideal ranges for samples made out with normal saline, as a 
solute is 3-5% weight percent. The samples made with 1.8% NaCl swell more, therefore 
should there be a significant (>10%) difference in volume between the implant itself and 
the dilated pocket, these should be the implants used. Based on their mechanical 



















Part 3: Thesis Discussion 
 
Chapter 16: Similarities and differences between cleft palate and facial 
implants 
 
The pharyngeal implant and facial (nasolabial and lip) implants designed through this 
research share some similarities but also present some strict differences, regarding 
primarily the role of each implant. Although they are both intended to fill respective 
voids/crevices in the targeted patients’ anatomy, the pharyngeal implant’s purpose is 
substantially constructive and non-cosmetic, and would lead to improving the patient’s 
speech production. Meanwhile, the facial implants, also volume filling implants, serve a 
cosmetic purpose. Additionally, due to the different areas of the body targeted for each 
implant, the pharyngeal implant presented higher risks based on each one’s first risk 
analysis: 6 potential failure modes with RPNs greater than 15, while the all the potential 
failure modes for the facial implants had RPNs below 15.  
The molding techniques for each product differ: The facial implants specific shape 
requires specific casting into a pre-made mold, while the pharyngeal implant’s generic 
cubical shape is molded using a simple tray of said shape. Furthermore, because the 
obturator includes a metallic frame as part of its design, the posterior polymeric part 
needs to be casted over the metallic frame during the molding process. 
The mechanical properties of these products also differ based on each one’s purpose. The 
facial implants, designed to be soft tissue fillers are the softest of the 3 products, and the 
range of PVA concentrations is 3% to 7.5% for the facial implants. Meanwhile, in order 
to provide a firm base that is not too hard, the pharyngeal implant’s range of PVA 
concentrations is 5% to 10%, whereas the obturator’s range is 20% to 30% to allow 
repeated removal and reinsertion without potential damage of the posterior part.  
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Aside from functional differences, one of the important differences between the facial 
implants and the pharyngeal implant is that the facial implants are preliminarily sized in a 
wide range, while the velopharyngeal implant’s size is determined on site based on the 
patient’s anatomy, and then carved out of a block of polymer by the physician. 
 
Chapter 17: Regulatory Pathway 
 
In the United States, the Food and Drug Administration is in charge of clearing or 
approving medical devices prior to commercialization and public usage. Based on their 
classification, purpose and risk, medical devices can different paths: Investigational 
Device Exemptions (IDE), Premarket Notification (510(k)), Premarket Approval 
Application (PMA) or Humanitarian Device Exemption (HDE). [64] 
In order to follow the 510(k) path, devices’ applications must show substantial 
similarities to FDA approved predicate devices, while the HDE path is reserved for 
devices that would benefit patients presenting diseases that affect 4000 people or less per 
year in the USA.  
This work focused on the design of solid, removable facial implants. Because there exist 
previous similar devices classified as 510(k)s (see table 33), the products designed by this 
work can  go through the 510(k) clearance pathway. It is important to note that, because 
only approximately 2650 babies are born in the United States with a cleft palate (<4000), 
both the pharyngeal implant and the obturator can follow the HDE pathway for FDA 
approval. For the HDE device clearance process, the devices are not required to prove 
effectiveness, but rather only limited risk. The following table lists all the relevant 
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Chapter 18: Analysis of Potential Devices Mechanical Failure 
 
Mechanical tests performed on the material were limited to compression, tensile and tear 
strength. There are however many other different forms of mechanical failure that can be 
tested for, including creep, fatigue, wear and yielding.   
Creeping manifests itself in solid materials by their slow movement or 
deformation over long times due to mechanical stresses exceeding the elastic limit.   
Wear is caused by surface friction from shear forces.   Fatigue is are specifically due to 
cyclic loading that exceed the Yield strength. Studies have evaluated PVA implants 
response to cyclic loading and wear in the case of cartilage implants (30-60% PVA). In 
these cases, it was shown that the thickness of the implant, the concentration of PVA and 
the surrounding material affect the level of wear occurring [30]. For example, implants 
shed more wear particles when cyclically loaded, creating shear forces with stainless steel 
than with articular cartilage. Given that significantly less loading on the implant is 
expected compared to the shoulder and the knee, it was deemed not important to 
perform tests that would observe these forms of mechanical failure; and the same 
observation was made for facial implants. 
 Creeping of the previously used PVA implants was not a concern highlighted by 
studies regarding mechanical failure [30]. 
Similarly for the obturator, the posterior part should be surrounded by tissues of similar 
elasticity (cartilage), and the tongue. The tongue is a muscle, which is less elastic than 
cartilage and less likely cause wear on obturator. Corrosion is a form of damage that 
could happen to the obturator when exposed to corrosive liquids, and this can be 
addressed by warning the users to keep the obturator away from such liquids. 
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Chapter 19: Part 3 Future work 
 
Based on the discussion regarding each device designed by this research, there is work to 
be done prior to FDA clearance for each device and implementation into commercially 
available devices. Regarding the pharyngeal implant, PVA having been proven to be a 
biocompatible material, the next step to take for this implant is to develop an efficient 
insertion method into the pharyngeal wall; which can be done via cadaver testing, 
similarly to that of the facial implants insertion method development.  
Regarding the obturators, their fabrication can be improved using current technologies. 
Because the shape of and size of the cleft vary per patient, it has been found difficult by 
physicians to streamline the fabrication of the devices. Using 3D imaging and 3D 
printing, molds for the obturators can be fabricated at the bedside based on the patients’ 
anatomy, reducing the current window of error due to casting of molds since this process 
involves attempting to immobilize the patient, which is a complicated task when it comes 
to patients that don’t easily follow directions (patients under 5).  
Regarding facial implants, the designs having been improved and insertion method 
developed, the next step to take is starting the FDA clearance process. An important 
question regarding the FDA clearance process also needs to be addressed,  which is 
whether the implants and the insertion kit should be marketed as a single device, or if the 
implants should be approved separately from the tools required from the insertion kit, and 
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